- Home
- RIGL vs KFS Comparison
RIGL vs KFS Comparison
Compare RIGL & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- KFS
- Stock Information
- Founded
- RIGL 1996
- KFS 1989
- Country
- RIGL United States
- KFS United States
- Employees
- RIGL N/A
- KFS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- KFS Property-Casualty Insurers
- Sector
- RIGL Health Care
- KFS Finance
- Exchange
- RIGL Nasdaq
- KFS Nasdaq
- Market Cap
- RIGL 335.5M
- KFS 417.8M
- IPO Year
- RIGL 2000
- KFS 1996
- Fundamental
- Price
- RIGL $38.85
- KFS $14.37
- Analyst Decision
- RIGL Buy
- KFS
- Analyst Count
- RIGL 5
- KFS 0
- Target Price
- RIGL $38.20
- KFS N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- KFS 69.0K
- Earning Date
- RIGL 08-05-2025
- KFS 08-07-2025
- Dividend Yield
- RIGL N/A
- KFS N/A
- EPS Growth
- RIGL N/A
- KFS N/A
- EPS
- RIGL 5.43
- KFS N/A
- Revenue
- RIGL $267,921,000.00
- KFS $119,287,000.00
- Revenue This Year
- RIGL $59.93
- KFS N/A
- Revenue Next Year
- RIGL N/A
- KFS N/A
- P/E Ratio
- RIGL $7.15
- KFS N/A
- Revenue Growth
- RIGL 105.62
- KFS 12.05
- 52 Week Low
- RIGL $12.66
- KFS $7.06
- 52 Week High
- RIGL $43.72
- KFS $16.80
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- KFS 54.71
- Support Level
- RIGL $39.00
- KFS $13.96
- Resistance Level
- RIGL $42.08
- KFS $14.36
- Average True Range (ATR)
- RIGL 2.32
- KFS 0.38
- MACD
- RIGL -0.37
- KFS 0.05
- Stochastic Oscillator
- RIGL 53.26
- KFS 89.60
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.